U.S. markets open in 2 hours 27 minutes

Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.1951+0.0013 (+0.67%)
At close: 04:00PM EDT
0.2049 +0.01 (+5.02%)
Pre-Market: 06:38AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close0.1938
Bid0.1925 x 1800
Ask0.1951 x 1300
Day's Range0.1900 - 0.2150
52 Week Range0.1800 - 0.6400
Avg. Volume920,264
Market Cap30.911M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SYN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Synthetic Biologics, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

    -Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- - Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team

  • Benzinga

    Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers

    Synthetic Biologics Inc (NYSE: SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days, with a follow-up evaluation at day 35. SYN-020 is a recombinant bovine IAP formulated for oral delivery to the small intestine and designed to diminish fat absorpti

  • GlobeNewswire

    Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

    -Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The